South Korea · Delayed Price · Currency is KRW HLB bioStep Statistics
Total Valuation
HLB bioStep has a market cap or net worth of KRW 43.10 billion. The enterprise value is 43.65 billion.
| Market Cap | 43.10B |
| Enterprise Value | 43.65B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB bioStep has 17.20 million shares outstanding. The number of shares has decreased by -1.55% in one year.
| Current Share Class | 17.20M |
| Shares Outstanding | 17.20M |
| Shares Change (YoY) | -1.55% |
| Shares Change (QoQ) | +3.98% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 1.49% |
| Float | 14.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 44.60 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.27 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -12.32 |
| Interest Coverage | -3.06 |
Financial Efficiency
Return on equity (ROE) is -18.70% and return on invested capital (ROIC) is -6.28%.
| Return on Equity (ROE) | -18.70% |
| Return on Assets (ROA) | -2.59% |
| Return on Invested Capital (ROIC) | -6.28% |
| Return on Capital Employed (ROCE) | -6.10% |
| Weighted Average Cost of Capital (WACC) | 4.63% |
| Revenue Per Employee | 490.82M |
| Profits Per Employee | -125.36M |
| Employee Count | 147 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 10.23 |
Taxes
In the past 12 months, HLB bioStep has paid 2.59 billion in taxes.
| Income Tax | 2.59B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.68% in the last 52 weeks. The beta is -0.01, so HLB bioStep's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -62.68% |
| 50-Day Moving Average | 2,283.92 |
| 200-Day Moving Average | 5,290.36 |
| Relative Strength Index (RSI) | 59.13 |
| Average Volume (20 Days) | 35,656 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB bioStep had revenue of KRW 72.15 billion and -18.43 billion in losses. Loss per share was -1,114.34.
| Revenue | 72.15B |
| Gross Profit | 53.18B |
| Operating Income | -6.29B |
| Pretax Income | -16.81B |
| Net Income | -18.43B |
| EBITDA | -1.48B |
| EBIT | -6.29B |
| Loss Per Share | -1,114.34 |
Balance Sheet
The company has 35.01 billion in cash and 31.02 billion in debt, with a net cash position of 4.00 billion or 232.42 per share.
| Cash & Cash Equivalents | 35.01B |
| Total Debt | 31.02B |
| Net Cash | 4.00B |
| Net Cash Per Share | 232.42 |
| Equity (Book Value) | 96.61B |
| Book Value Per Share | 5,433.22 |
| Working Capital | 11.72B |
Cash Flow
In the last 12 months, operating cash flow was 966.24 million and capital expenditures -3.48 billion, giving a free cash flow of -2.52 billion.
| Operating Cash Flow | 966.24M |
| Capital Expenditures | -3.48B |
| Depreciation & Amortization | 4.81B |
| Net Borrowing | 648.77M |
| Free Cash Flow | -2.52B |
| FCF Per Share | -146.30 |
Margins
Gross margin is 73.70%, with operating and profit margins of -8.71% and -25.54%.
| Gross Margin | 73.70% |
| Operating Margin | -8.71% |
| Pretax Margin | -23.30% |
| Profit Margin | -25.54% |
| EBITDA Margin | -2.05% |
| EBIT Margin | -8.71% |
| FCF Margin | n/a |
Dividends & Yields
HLB bioStep does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.55% |
| Shareholder Yield | 1.55% |
| Earnings Yield | -42.76% |
| FCF Yield | -5.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
HLB bioStep has an Altman Z-Score of 2.16 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.16 |
| Piotroski F-Score | 5 |